Anebulo Pharmaceuticals (ANEB) Common Equity (2020 - 2025)

Anebulo Pharmaceuticals (ANEB) has reported Common Equity for 6 consecutive years, with $7.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Common Equity fell 46.96% year-over-year to $7.9 million; the TTM figure through Dec 2025 stood at $7.9 million (down 46.96% YoY), while the FY2025 annual figure was $11.7 million, up 205.78% from the prior year.
• Common Equity eased to $7.9 million in Q4 2025 per ANEB's latest filing, from $9.7 million in the prior quarter.
• Across five years, Common Equity topped out at $21.4 million in Q2 2021 and bottomed at -$9.4 million in Q1 2021.
• Historically, Common Equity has averaged $11.2 million across 5 years, with a median of $12.3 million in 2023.
• Annual changes were most pronounced in 2021 — Common Equity surged 12611.53% — and 2024, when it sank 77.21%.
• Anebulo Pharmaceuticals' Common Equity stood at $18.9 million in 2021, then slipped by 17.97% to $15.5 million in 2022, then slumped by 58.19% to $6.5 million in 2023, then jumped by 130.64% to $15.0 million in 2024, then tumbled by 46.96% to $7.9 million in 2025.
• Business Quant data shows ANEB's Common Equity at $7.9 million in Q4 2025, $9.7 million in Q3 2025, and $11.7 million in Q2 2025.